TRANSITION PLAN

 Jennifer Simpson and Graham Miao Appointed Interim Co-President and Co-Chief
Executive Officer; Gabriel Leung Appointed Chairman of the Board of Directors

New York, NY - September 13, 2013 - Delcath Systems, Inc. (NASDAQ: DCTH), a
specialty pharmaceutical and medical device company focused on oncology,
announced today that the Company's Board of Directors has implemented a
leadership transition plan under which Jennifer Simpson, Ph.D., M.S.N.,
C.R.N.P., the Company's current Executive Vice President, Global Head of
Business Operations, and Graham Miao, Ph.D., M.S., MBA the Company's current
Executive Vice President and Chief Financial Officer, have been appointed to
serve as Interim Co-President and Co-Chief Executive Officers. The employment
of Eamonn P. Hobbs as President and Chief Executive Officer with the Company
was terminated as of September 10, 2013; Mr. Hobbs has also resigned from the
Board of Directors. In addition to her role as Interim Co-President and
Co-Chief Executive Officer, Dr. Simpson shall continue to serve as the
Company's Executive Vice President, Global Head of Business Operations. In
addition to his role as Interim Co-President and Co-Chief Executive Officer,
Dr. Miao shall continue to serve as the Company's Executive Vice President,
Chief Financial Officer. 

In addition, under the transition plan, Gabriel Leung has been appointed
Chairman of the Board. Mr. Leung has been a member of the Board of Directors
since 2011 and brings more than 20 years experience in the oncology
pharmaceuticals marketplace to Delcath. He replaces Dr. Harold Koplewicz as
Chairman, who remains a member of the Board of Directors. The Board has also
appointed a Transition Committee to assist the Board and management with the
leadership transition including the search process for the next President and
Chief Executive Officer of the Company. This Committee will also assist the
Board in its rigorous evaluation of potential strategic options for the
Company going forward. The initial members of this committee are current
Board members Douglas Watson and Roger Stoll, as well as Dr. Koplewicz and Mr.

"The Delcath Board of Directors believes these actions are in the best
interests of the Company and its shareholders. I look forward to working with
the senior management team and the Board Transition Committee as we evaluate
our strategy and develop our implementation plan," said Mr. Leung.

Background on Drs. Simpson and Miao, Mr. Leung

Dr. Simpson joined Delcath in 2012, and has an extensive background in
pharmaceutical and oncology product development, clinical trials and global
marketing. Prior to her appointment atDelcath, Dr. Simpson served as the Vice
President, Global Marketing, Oncology Brand Lead atImClone Systems, Inc.(a
wholly- owned subsidiary ofEli Lilly and Company). In this role, she was
responsible for all product commercialization activities and launch
preparation for one of the late stage assets. While at ImClone, Dr. Simpson
also held various positions of increasing responsibility including serving as
the Vice President, Product Champion and the Associate Vice President, Product
Champion. Previously, Dr. Simpson held several leadership positions at Ortho
Biotech (now Janssen Biotech), a Pennsylvania-based biotech company that
focuses on innovative solutions in immunology, oncology and nephrology. Prior
to her time at Ortho Biotech, Dr. Simpson spent over a decade as an
oncology-nurse practitioner and educator.

Dr. Miao joined Delcath in 2011 as Executive Vice President and Chief
Financial Officer and is a senior financial executive with extensive
experience in global business operations, financial planning and analysis, and
business development inthe United States,AsiaandEurope. Previously, he
served as Chief of Staff of the Global CFO Organization and member of the
Financial Leadership team of Dun & Bradstreet Corporation. Prior to joining
Dun & Bradstreet, Dr. Miao was Executive Vice President & CFO of Pagoda
Pharmaceuticals--aShanghai-based specialty pharmaceuticals and medical device
company focused in urology and allergy. In addition, Dr. Miao has held
various leadership positions, including division CFO roles, with Symrise,
Inc., Schering-Plough Corporation and Pharmacia Corporation, and served as a
biotech equity analyst with J.P. Morgan.  

Mr. Leung joined the Delcath Board of Directors in March 2011, and holds a
wealth of experience in successfully gaining regulatory approval for and
launching oncology drugs. Mr. Leung previously served as President of the
Pharmaceuticals Business at OSI Pharmaceuticals, overseeing its oncology,
diabetes and obesity businesses prior to the Company's acquisition by Astellas
Pharma Inc. in June 2010. During his seven years at OSI, Mr. Leung held
several senior management positions, led the successful filing of two
supplemental New Drug Applications (NDA) for Tarceva(R) (erlotinib) and guided
it to one of the most successful launches in the U.S. oncology marketplace.
During Mr. Leung's tenure, OSI's market capitalization increased from $1.4
billion to approximately $4.0 billion at the time of acquisition. Prior to
OSI, Mr. Leung served as Group Vice President, Global Prescription Business &
Head of the Global Oncology Franchise for Pharmacia Corporation. At Pharmacia,
Mr. Leung served on the CEO's Corporate Operating Committee, overseeing the
global oncology franchise and all oncology clinical development projects and
the discovery portfolio strategy that led to four successful ODAC panel
recommendations and NDA/sNDA approvals. Previously, Mr. Leung held several
leadership positions at Bristol-Myers Squibb. Currently, Mr. Leung serves on
the Board of Directors of Albany Molecular Research, Inc., and is Executive
Vice Chairman of the Board and Chair of the Global Commercialization Team of
Novocure, Ltd., a privately-held oncology medical device company.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on oncology. Our proprietary drug/device combination product, the
Delcath Hepatic Delivery System, is designed to administer high dose
chemotherapy and other therapeutic agents to the liver, while controlling the
systemic exposure of those agents. The Company's initial focus is on the
treatment of primary and metastatic liver cancers. Outside of the United
States, our proprietary product to deliver and filter melphalan hydrochloride
is marketed under the trade name Delcath Hepatic CHEMOSAT® Delivery System for
melphalan hydrochloride. The Company obtained authorization to affix a CE Mark
for the Generation Two CHEMOSAT Delivery System for Melphalan in April 2012.
The right to affix the CE mark allows the Company to market and sell the
CHEMOSAT Delivery System for Melphalan in Europe. In addition, the Company has
initiated plans to investigate the Melblez Kit for primary liver cancer. For
more information, please visit the Company's website at

Private Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are subject to certain
risks and uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences include, but are
not limited to, uncertainties relating to: the leadership transition plan and
its impact on the Company, the Company's ability to satisfy the requirements
of the FDA's Complete Response Letter and provide the same in a timely
manner, clinical adoption, use and resulting sales, if any, for the CHEMOSAT
system to deliver and filter melphalan in Europe, our ability to successfully
commercialize the chemosaturation system and the potential of the
chemosaturation system as a treatment for patients with primary and metastatic
disease in the liver, our ability to obtain reimbursement for the CHEMOSAT
system in various markets, the timing and results of future clinical trials
including without limitation the HCC trials, approval of the current or future
chemosaturation system for delivery and filtration of melphalan, doxorubicin
or other chemotherapeutic agents for various indications in the US and/or in
foreign markets, actions by the FDA or other foreign regulatory agencies, our
ability to successfully enter into strategic partnership and distribution
arrangements in foreign markets including Australia and key Asian markets and
timing and revenue, if any, of the same, uncertainties relating to the timing
and results of research and development projects,, and uncertainties regarding
our ability to obtain financial and other resources for any research,
development, clinical trials and commercialization activities. These factors,
and others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made. We
undertake no obligation to publicly update or revise these forward-looking
statements to reflect events or circumstances after the date they are made.

Investor Contact:                Media Contact:
Michael Polyviou/Patty Eisenhaur John Carter
EVC Group                        EVC Group
212-850-6020/951-316-0577        212-850-6021



This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.